Drug (ID: DG01713) and It's Reported Resistant Information
Name
Azacitidine/Sorafenib
Synonyms
Azacitidine/Sorafenib
    Click to Show/Hide
Target . NOUNIPROTAC [1]
Type(s) of Resistant Mechanism of This Drug
  UAPP: Unusual Activation of Pro-survival Pathway
Drug Resistance Data Categorized by Their Corresponding Diseases
ICD-02: Benign/in-situ/malignant neoplasm
Click to Show/Hide the Resistance Disease of This Class
Acute myeloid leukemia [ICD-11: 2A60]
Click to Show/Hide
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms
       Unusual Activation of Pro-survival Pathway (UAPP) Click to Show/Hide
Key Molecule: Receptor-type tyrosine-protein kinase FLT3 (FLT3) [1]
Molecule Alteration IF-insertion
p.Y599_D600insSTDNEYFYVDFREYEY (c.1797_1798insAGCACAGACAACGAGTATTTTTATGTAGACTTTAGGGAGTATGAGTAT)
Sensitive Disease Acute myeloid leukemia [ICD-11: 2A60.0]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Bone marrow N.A.
Mechanism Description The if-insertion p.Y599_D600insSTDNEYFYVDFREYEY (c.1797_1798insAGCACAGACAACGAGTATTTTTATGTAGACTTTAGGGAGTATGAGTAT) in gene FLT3 cause the sensitivity of Azacitidine + Sorafenib by unusual activation of pro-survival pathway.
References
Ref 1 Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutationBlood. 2013 Jun 6;121(23):4655-62. doi: 10.1182/blood-2013-01-480228. Epub 2013 Apr 23.

If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.